Renal Biomarkers MarketSize and Trends

The global renal biomarkers market is estimated to be valued at US$ 1,476.2 million in 2023 and is expected to exhibit a CAGR of 8.2% during the forecast period (2023-2030).

Figure 1. Global Renal Biomarkers Market Share (%), by Biomarker Type, 2023

Global Renal Biomarkers Market– Driver

Rising incidence of chronic kidney diseases and growing geriatric population

Rising incidence of chronic kidney diseases is expected to boost the growth of the global renal biomarkers market over the forecast period. For instance, according to an article in british medical journal in January 2020, the number of dialysis patients on the kidney transplant waiting list as of December, 2017 marked a third consecutive year of decline with an 8.8% reduction from the previous year, to 75,745 candidates, 85% of whom were awaiting their first kidney transplant. The waiting period increases the prevalence of CKD.

Product Launch from the key players

Over the forecast period, key players' newly released products typically drive the renal biomarkers market. For instance, on May 16, 2023, Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced positive new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC) and new data from a biomarker high subgroup.

Global Renal Biomarkers Market Segmentation:

The global renal biomarkers market report is segmented into Biomarker Type, Technique, End user and Region.

By Biomarker Type, the renal biomarkers market is segmented into Functional Biomarkers and Up-Regulated Proteins. Out of which, the functional biomarkers segment is expected to hold a dominant position in the global renal biomarkers market during the forecast period and the Cystatin C which is one of the segments of functional biomarkers is expected to dominate over the forecast period. For instance, in March 2021, according to an article published in the Journal of Scientific Reports, suggests that Cystatin C-based estimations of kidney function performed better than creatinine-based ones in patients with primary neuromuscular disease but most importantly, all evaluated equations overestimated kidney function, especially in patients with reduced kidney function. Therefore, kidney function should be measured by gold-standard methods when precision and accuracy are needed.

By Technique, the renal biomarkers market is segmented into Enzyme Linked Immunosorbent Assay (ELISA), Particle-Enhanced Turbidimetric Immunoassay, Calorimetric Assay, Chemiluminescent Enzyme Immunoassay, and Liquid Chromatography-Mass Spectrometry. The ELISA segment is expected to dominate the market over the forecast period and this is due to the increasing usage for the diagnosis of chronic kidney diseases.

By End User, the renal biomarkers market is segmented into diagnostics labs, outpatient clinics, research centers and hospitals. The hospital segment is expected to dominate the market over the forecast period and this is attributed to the increasing prevalence of kidney diseases. For instance, in May 2020, according to Pan American Health Organisation, in 2019 the mortality in region-wide kidney diseases account for 254,028 total deaths, 131,008 deaths in men, and 123,020 deaths in women. The age-standardized death rate due to kidney diseases was estimated at 15.6 deaths per 100,000 population. Age-standardized death rates from kidney diseases vary across countries from a high in Nicaragua (73.9 deaths per 100,000 population) to a low in Canada (5.0 deaths per 100,000 population).

Among all segmentation, the End user segment has the highest potential due to the increasing product launch by the key market players. For instance, in July 2022, Healthy.io, a health care company, announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for home use of the Minuteful Kidney test. The FDA has never before approved a smartphone-powered at-home test to measure the albumin to creatinine ratio (ACR).

Global Renal Biomarkers Market: Key Trends

Rising demand for kidney disease diagnosis, increasing collaboration agreement between the key players, and launch of new products.

Due to the increase in the demand for diagnostic tools for kidney diseases, key players in the market are undergoing various strategic development over the forecast period.

Players in the market are focused on developing feline renal biomarkers. For instance, in February 2020, Antech Diagnostics, a part of Mars Petcare, launched Antech SDMA (symmetric dimethylarginine), a feline renal biomarker for early diagnosis, staging and monitoring of chronic kidney disease.

Market- Trends